OBJECTIVES The aim of this study was to assess acute regurgitation following transcatheter aortic valve replacement, comparing different implanted transcatheter heart valves. BACKGROUND Regurgitation following transcatheter aortic valve replacement in fluences all -cause mortality. Thus far, no quantitative comparison of regurgitation among multiple commercially available transcatheter heart valves has been performed. METHODS Aortograms from a multicenter cohort of consecutive 3,976 transcatheter aortic valve replacements were evaluated in this pooled analysis. A total of 2,258 (58.3%) were considered analyzable by an independent academic core laboratory using video densitometry. Results of quantitative regurgitation are shown as percentages. The valves eval- uated were the ACURATE (n = 115), Centera (n = 11), CoreValve (n = 532), Direct Flow Medical (n = 21), Evolut PRO (n = 95), Evolut R (n = 295), Inovare (n = 4), Lotus (n = 546), Lotus Edge (n = 3), SAPIEN XT (n = 239), and SAPIEN 3 (n = 397). For the main analysis, only valves with more than 50 procedures (7 types) were used. RESULTS The Lotus valve had the lowest mean regurgitation (3.5 +/- 4.4%), followed by Evolut PRO (7.4 +/- 6.5%), SAPIEN 3 (7.6 +/- 7.1%), Evolut R (7.9 +/- 7.4%), SAPIEN XT (8.8 +/- 7.5%), ACURATE (9.6 +/- 9.2%) and CoreValve (13.7 +/- 10.7%) (analysis of variance p < 0.001). The only valves that statistically differed from all their counterparts were Lotus (as the lowest regurgitation) and CoreValve (the highest). The proportion of patients presenting with moderate or severe regurgitation followed the same ranking order: Lotus (2.2%), Evolut PRO (5.3%), SAPIEN 3 (8.3%), Evolut R (8.8%), SAPIEN XT (10.9%), ACURATE (11.3%), and CoreValve (30.1%) (chi-square p < 0.001). CONCLUSIONS In this pooled analysis stemming from daily clinical practice, the Lotus valve was shown to have the best immediate sealing. This analysis re flects the objective evaluation of regurgitation by an academic core laboratory (nonsponsored) in a real -world cohort of patients using a quantitative technique.
Quantitative Assessment of Acute Regurgitation Following TAVR A Multicenter Pooled Analysis of 2,258 Valves / Modolo, R; Chang, Cc; Abdelghani, M; Kawashima, H; Ono, M; Tateishi, H; Miyazaki, Y; Pighi, M; Wykrzykowska, Jj; de Winter, Rj; Ruck, A; Chieffo, A; van Mourik, Ms; Yamaji, K; de Brito, Fs; Lemos, Pa; Al-Kassou, B; Piazza, N; Tchetche, D; Sinning, Jm; Abdel-Wahab, M; Soliman, O; Sondergaard, L; Mylotte, D; Onuma, Y; Van Mieghem, Nm; Serruys, Pw. - In: JACC: CARDIOVASCULAR INTERVENTIONS. - ISSN 1936-8798. - 13:11(2020), pp. 1303-1311. [10.1016/j.jcin.2020.03.002]
Quantitative Assessment of Acute Regurgitation Following TAVR A Multicenter Pooled Analysis of 2,258 Valves
Chieffo A;
2020-01-01
Abstract
OBJECTIVES The aim of this study was to assess acute regurgitation following transcatheter aortic valve replacement, comparing different implanted transcatheter heart valves. BACKGROUND Regurgitation following transcatheter aortic valve replacement in fluences all -cause mortality. Thus far, no quantitative comparison of regurgitation among multiple commercially available transcatheter heart valves has been performed. METHODS Aortograms from a multicenter cohort of consecutive 3,976 transcatheter aortic valve replacements were evaluated in this pooled analysis. A total of 2,258 (58.3%) were considered analyzable by an independent academic core laboratory using video densitometry. Results of quantitative regurgitation are shown as percentages. The valves eval- uated were the ACURATE (n = 115), Centera (n = 11), CoreValve (n = 532), Direct Flow Medical (n = 21), Evolut PRO (n = 95), Evolut R (n = 295), Inovare (n = 4), Lotus (n = 546), Lotus Edge (n = 3), SAPIEN XT (n = 239), and SAPIEN 3 (n = 397). For the main analysis, only valves with more than 50 procedures (7 types) were used. RESULTS The Lotus valve had the lowest mean regurgitation (3.5 +/- 4.4%), followed by Evolut PRO (7.4 +/- 6.5%), SAPIEN 3 (7.6 +/- 7.1%), Evolut R (7.9 +/- 7.4%), SAPIEN XT (8.8 +/- 7.5%), ACURATE (9.6 +/- 9.2%) and CoreValve (13.7 +/- 10.7%) (analysis of variance p < 0.001). The only valves that statistically differed from all their counterparts were Lotus (as the lowest regurgitation) and CoreValve (the highest). The proportion of patients presenting with moderate or severe regurgitation followed the same ranking order: Lotus (2.2%), Evolut PRO (5.3%), SAPIEN 3 (8.3%), Evolut R (8.8%), SAPIEN XT (10.9%), ACURATE (11.3%), and CoreValve (30.1%) (chi-square p < 0.001). CONCLUSIONS In this pooled analysis stemming from daily clinical practice, the Lotus valve was shown to have the best immediate sealing. This analysis re flects the objective evaluation of regurgitation by an academic core laboratory (nonsponsored) in a real -world cohort of patients using a quantitative technique.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
